

CITATION REPORT

List of articles citing

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

DOI: 10.7326/0003-4819-111-12-992

Annals of Internal Medicine, 1989, 111, 992-1000.

Source: <https://exaly.com/paper-pdf/21027747/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
601	Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. 1989 , 38, 863-99		64
600	Erythropoietin-associated hypertension. 1990 , 323, 999-1000		22
599	Erythropoietin: regulation of erythropoiesis and clinical use. 1990 , 21, 127-47		2
598	Haematology. 1990 , 66, 595-611		1
597	Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. 1990 , 16, 101-8		20
596	Quality of life assessment and the treatment of end-stage renal disease. 1990 , 4, 28-51		27
595	Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. 1990 , 89, 161-8		203
594	Erythropoietin: Physiology and clinical applications. 1991 , 9, 105-120		
593	The effect of hematocrit on peritoneal transport. 1991 , 18, 573-8		18
592	Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. 1991 , 18, 60-4		17
591	Use of low-dose subcutaneous recombinant human erythropoietin in end-stage renal disease: experience with children receiving continuous cycling peritoneal dialysis. 1991 , 18, 446-50		14
590	Impact of epoetin beta on dialyzer clearance and heparin requirements. 1991 , 18, 668-73		15
589	Quality of life. 1991 , 338, 636-637		20
588	The potential of biotechnology to improve the quality of life of patients with renal failure. 1991 , 6, 1-7		8
587	Use of recombinant human erythropoietin to enhance autologous blood donation in a patient with multiple red cell allo-antibodies and the anemia of chronic disease. 1991 , 90, 398-400		6
586	Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. 1991 , 91, 229-32		20
585	Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. 1991 , 21, 693-700		33

584	The role of erythropoietin and other growth factors in transfusion medicine. 1991 , 5, 33-47	8
583	The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised host. 1991 , 2, 74-88	2
582	Blood and blood products. 1991 , 15, 364-377	
581	Erythropoietin--trials then tribulation. 1991 , 36, 3-4	3
580	Recombinant erythropoietin and chronic renal failure. 1991 , 26, 61-9	2
579	New developments in pediatric nephrology. 1991 , 21, 121-8	1
578	Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients. 1991 , 29, 35-45	47
577	rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. 1991 , 39, 155-63	182
576	Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. 1991 , 78, 488-93	48
575	Autologous transfusion--too far, too soon?. 1991 , 61, 81-3	9
574	Cytokine biology. Implications for transfusion medicine. 1991 , 67, 2708-11	6
573	Erythropoiesis and erythropoietin levels in renal transplant recipients. 1991 , 69, 53-8	24
572	Haematopoietic growth factors. 1991 , 3, 61-3	
571	Chronic peritoneal dialysis in the elderly. 1991 , 1, 3-12	17
570	Overview of Biotechnology in Health Care. 1991 , 4, 80-86	
569	Recombinant erythropoietin to improve athletic performance. 1991 , 324, 698-9	54
568	Chronic renal insufficiency in infants and children. 1991 , 30, 365-84	11
567	Hematopoietic growth factors in clinical hematology. 1991 , 23, 615-24	6

566	Erythropoietin. 1991 , 324, 1339-44	326
565	Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO). 1992 , 31, 94-9	15
564	Erythropoietin therapy obviates the need for recurrent transfusions in a patient with severe hemolysis due to prosthetic valves. 1992 , 102, 315-6	10
563	The Effect of Recombinant Hump Erythropoietin Therapy in Anemic Kidney Patients: A Nutritional Emphasis. 1992 , 2, 96-104	1
562	Anemia of renal failure. Use of erythropoietin. 1992 , 76, 711-25	20
561	Management of the oral and maxillofacial surgery patient with end-stage renal disease. 1992 , 50, 1207-12	15
560	Controversies in determination of epoetin (recombinant human erythropoietin) dosages. 1992 , 22, 409-15	12
559	The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. 1992 , 19, 484-9	13
558	Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. 1992 , 46, 65-8	16
557	Hemopoietic growth factors: a review. 1992 , 32, 486-501	12
556	Blood Pressure after three Different forms of Correction of Anemia in Hemodialysis. 1992 , 15, 393-396	11
555	Erythropoietin and Peritoneal Dialysis: The Efficacy of Intraperitoneal Dosing. 1992 , 12, 350-352	10
554	Intraperitoneal Administration of Recombinant Human Erythropoietin. 1992 , 12, 378-383	21
553	A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. 1992 , 42, 407-16	53
552	Effects of short-term administration of recombinant human erythropoietin on rat megakaryopoiesis. 1992 , 10, 18-27	12
551	Erythropoietin. 1992 , 2, 1-7	2
550	Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation. 1992 , 80, 545-9	11
549	A decade of rare donor services in the United States. Report of the American Red Cross Rare Donor Registry (1981-1990). 1992 , 63, 186-91	16

- 548 Biology and pharmacology of hematopoietic growth factors. **1992**, 2, 2-9 5
- 547 Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease. **1993**, 7, 276-80 31
- 546 Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. **1993**, 43, 1010-4 154
- 545 Early dosing practices and effectiveness of recombinant human erythropoietin. **1993**, 43, 1125-33 27
- 544 Erythropoietin: physiologic basis for clinical applications. **1993**, 65, 169-79 10
- 543 Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. **1993**, 328, 171-5 312
- 542 Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates?. **1993**, 165, 650-4 12
- 541 Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. **1993**, 94, 401-6 45
- 540 Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. **1993**, 3, 45-82 18
- 539 Recombinant erythropoietin overdose. **1993**, 11, 619-21 6
- 538 Case 1--1993. The role of erythropoietin in Jehovah's Witnesses requiring cardiac surgery. **1993**, 7, 95-102 6
- 537 Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. **1993**, 22, 557-67 10
- 536 National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. **1993**, 22, 3-12 78
- 535 Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin. **1993**, 21, 31-7 78
- 534 Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. **1993**, 341, 1227-1232 180
- 533 The end stage renal disease program. **1993**, 329, 139; author reply 140-1
- 532 Iron management during treatment with recombinant human erythropoietin in chronic renal failure. **1993**, 33, 1134-8 4
- 531 Is a hemoglobin of 10 g/dL required for surgery?. **1993**, 77, 335-47 39

530	Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin. 1993 , 9, 490-504	12
529	Effect of Erythropoietin Treatment on Nutritional Status of Continuous Ambulatory Peritoneal Dialysis Patients. 1993 , 13, 544-549	6
528	Influence of Erythropoietin on Blood Pressure in Continuous Ambulatory Peritoneal Dialysis Patients. 1993 , 13, 553-557	3
527	Effect of Recombinant Erythropoietin on Electrolytes and Nutrition in End-Stage Renal Disease Patients. 1993 , 16, 59-62	3
526	Haemostasis and Vascular Disease in Dialysis Patients Receiving Erythropoietin Therapy. 1993 , vnr-4, 171-182	
525	Clinical Application of Recombinant Erythropoietin in Renal Dialysis Patients. 1994 , 8, 913-926	4
524	Clinical Application of Recombinant Erythropoietin in the Anemia of Chronic Disease. 1994 , 8, 933-944	13
523	Seizures and Renal Failures. 1994 , 17, 247-251	16
522	Seizures in Dialysis Patients Treated with Recombinant Erythropoietin. Review of the Literature and Guidelines for Prevention. 1994 , 17, 5-13	33
521	Erythropoietin Treatment in Peritoneal Dialysis Patients. 1994 , 14, 63-69	4
520	Intradialytic Oral Iron Therapy. 1994 , 17, 261-264	13
519	Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy. 1994 , 16, 565-75	39
518	Optimizing the effectiveness of hematopoietic growth factors. 1994 , 14, 215-23	6
517	Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?. 1994 , 8, 51-6	19
516	Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. 1994 , 87, 153-61	28
515	Hemostasis in renal disease: pathophysiology and management. 1994 , 96, 168-79	113
514	Influence of erythropoietin on dialyzer reuse, heparin need, and urea kinetics in maintenance hemodialysis patients. 1994 , 23, 52-9	10
513	Effect of recombinant erythropoietin therapy on autoimmunity in systemic lupus erythematosus. 1994 , 24, 25-32	11

512	Early adoption of cyclosporine and recombinant human erythropoietin: clinical, economic, and policy issues with emergence of high-cost drugs. 1994 , 24, 33-41	6
511	The application of nutritional science to clinical practice. 1994 , 53, 1-14	3
510	Vocational rehabilitation in maintenance dialysis patients. 1994 , 1, 228-39	5
509	Impotence and chronic renal failure: a study of the hemodynamic pathophysiology. 1994 , 151, 612-8	76
508	Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement. 1994 , 5, 18-28	7
507	Pharmacotherapeutic consequences of recent advances in hemodialysis therapy. 1994 , 28, 512-4	9
506	New hormones in the therapeutic arsenal of chronic renal failure. Growth hormone and erythropoietin. 1995 , 42, 1551-77	17
505	Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. 1995 , 90, 341-5	42
504	Red blood cell cation transports in uraemic anaemia: evidence for an increased K/Cl co-transport activity. Effects of dialysis and erythropoietin treatment. 1995 , 25, 762-8	5
503	Megakaryocytopoiesis: cellular aspects and regulation. 1995 , 20, 165-92	17
502	Human megakaryocyte biology and pathophysiology. 1995 , 21, 135-57	18
501	Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. 1995 , 48, 806-13	62
500	Pretreatment Hemoglobin and Response to Erythropoietin in CAPD Patients. 1995 , 15, 174-176	
499	The Role of Hematopoietic Growth Factors in Transfusion Medicine. 1995 , 9, 23-68	12
498	Pressor effect of recombinant human erythropoietin: results of ambulatory blood pressure monitoring and home blood pressure measurements. 1995 , 17, 485-506	16
497	Serum immunoreactive erythropoietin in health and disease. 1995 , 23, 13-7	13
496	Erythropoietin—from gene structure to therapeutic applications. 1995 , 23, 77-81	8
495	Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. 1995 , 19, 188-91	14

494	Quantitative reticulocyte analysis may be of benefit in monitoring erythropoietin treatment in dialysis patients. 1995 , 19, 821-6	4
493	Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. 1995 , 170, 37S-43S	36
492	Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. 1995 , 49, 232-54	79
491	L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. 1995 , 26, 757-64	104
490	Pharmacological approaches to reduce perioperative transfusion requirements in the aged. 1995 , 6, 91-104	5
489	Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. 1995 , 7, 131-56	8
488	Controversies in selection of epoetin dosages. Issues and answers. 1995 , 49, 536-47	20
487	Changing concepts of nutrient requirements in disease: implications for artificial nutritional support. 1995 , 345, 1279-84	84
486	Recombinant growth factors. 1995 , 16, 45-62	3
485	Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. 1995 , 26, 331-40	50
484	Evidence-based recommendations for the clinical use of recombinant human erythropoietin. 1995 , 26, S1-24	70
483	Hypoxia, Erythropoietin Gene Expression, and Erythropoiesis. 1996 , 1125-1153	1
482	Cytokines. 1996 , 14, 331-6	3
481	Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. 1996 , 129, 656-60	63
480	The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states. 1996 , 28, 235-49	8
479	Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. 1996 , 28, 910-7	70
478	Hematopoietic growth factors in clinical practice. 1996 , 12, 115-29	1
477	Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin. 1996 , 18, 51-64	3

476	Recombinant human erythropoietin therapy in children on dialysis. 1996 , 3, 24-36	21
475	A case of bone pain caused by erythropoietin. 1996 , 1, 61-62	
474	The effects of recombinant human erythropoietin on growth and nutritional status. 1996 , 10, 324-7	39
473	Megakaryocytopoiesis in vitro: from the stem cells' perspective. 1996 , 14 Suppl 1, 163-72	7
472	The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. 1996 , 334, 420-5	197
471	Anemia, dialysis, and dollars. 1996 , 334, 461-3	3
470	Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. 1997 , 31, 15-22	48
469	Hematopoiesis. 1997 , 3, 157-189	
468	Haemopoietic growth factors. 1997 , 73, 215-21	8
467	Some Hemostatic Changes During the Course of Hemodialysis in Patients with Erythropoietin Treatment. 1997 , 3, 141-143	1
466	Cardiac disease in chronic uremia: management. 1997 , 4, 249-66	8
465	Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. 1997 , 52, 217-22	155
464	Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. 1997 , 30, 165-73	50
463	Iron management in end-stage renal disease. 1997 , 29, 319-33	142
462	Endogenous erythropoietin correlates with blood pressure in essential hypertension. 1997 , 29, 376-82	16
461	Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. 1997 , 30, 532-41	47
460	Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. 1997 , 89, 4248-4267	218
459	Erythropoietin 1997: A Brief Update. 1997 , 17, 84-90	75

458	Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. 1997 , 51, 622-30	93
457	5d Erythropoietin and iron in autologous haemotherapy. 1997 , 11, 351-362	1
456	Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions. 1997 , 15, 286-90	21
455	Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. 1998 , 77, 1996-2002	54
454	Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. 1998 , 187, 616-9	14
453	Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function. 1998 , 59, 105-9	27
452	Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996. 1998 , 54, 2129-39	17
451	Recombinant human erythropoietin increases platelet aggregation in chronic hemodialysis patients. 1998 , 90, 195-8	5
450	Bethesda conference: conference for the design of clinical trials to study circulatory support devices for chronic heart failure. 1998 , 66, 1452-1465	13
449	General classes and functions of four-helix bundle cytokines. 1998 , 52, 1-65	27
448	Dose escalation induces tolerance to side-effects of erythropoietin in a patient with dialysis anaemia: case report. 1998 , 26, 102-5	4
447	Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. 1998 , 339, 578-83	254
446	Erythropoietin for end-stage renal disease. 1998 , 339, 625-7	49
445	Care of patients undergoing hemodialysis. 1998 , 339, 1054-62	64
444	The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. 1998 , 339, 584-90	1674
443	The Effect of Hematopoietic Growth Factors on Platelet Aggregability. 1998 , 4, 238-242	1
442	Uremic Bleeding: Pathogenesis and Therapy. 1998 , 316, 94-104	1
441	Pharmacotherapeutics of Biotechnology-Derived Products. 1998 , 11, 54-71	

440	Erythropoietin Prevents the Development of Interleukin-12-Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice. 1998 , 91, 4387-4388	12
439	The Effect of Recombinant Human Erythropoietin on Platelet Counts Is Strongly Modulated by the Adequacy of Iron Supply. 1999 , 93, 3286-3293	62
438	Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. 1999 , 14, 2680-7	139
437	Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia. 1999 , 5, 22-31	2
436	Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. 1999 , 10 Suppl 5, S91-4	17
435	Erythropoietin in the neonate. 1999 , 29, 129-49	25
434	Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. 1999 , 56, 253-60	30
433	Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. 1999 , 69, S35-43	55
432	Erythropoietin and renal transplantation. 1999 , 69, S86-92	20
431	A Consensus on Current Issues and Controversies in Iron Management of Patients with Chronic Renal Failure. 1999 , 12, 182-194	3
430	Parenteral Iron Therapy: Safety and Efficacy. 1999 , 12, 237-242	4
429	Worsening of left ventricular diastolic function during long-term correction of anemia with erythropoietin in chronic hemodialysis patients--an assessment by radionuclide ventriculography at rest and exercise. 1999 , 15, 233-9	6
428	[Iron supplementation in preterm infants treated with erythropoietin]. 1999 , 6, 657-64	6
427	What crit?. 1999 , 33, 1177-9	1
426	Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient. 1999 , 34, 349-54	23
425	Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. 1999 , 21, 1443-55; discussion 1427-8	36
424	Implementation of the Anemia Guidelines. 1999 , 6, 18-27	3
423	The impact of the Dialysis Outcomes Quality Initiative Guidelines on the care of the pediatric end-stage renal disease patient. 1999 , 6, 97-106	12

422	End-stage renal disease (ESRD) and vascular access grafting: a critical review. 1999 , 13, 297-350	4
421	Clinical Applications of Recombinant Human Erythropoietin. 2000 , 29-57	2
420	Biphasic Changes in Nitric Oxide Generation in Hemodialyzed Patients with End-Stage Renal Disease Treated with Recombinant Human Erythropoietin. 2000 , 319, 149-157	2
419	Blood volume: importance and adaptations to exercise training, environmental stresses, and trauma/sickness. 2000 , 32, 332-48	259
418	Antithrombotic agents and the prevention of access thrombosis. 2000 , 13, 40-6	21
417	Target haemoglobin levels for the treatment of the anaemia of chronic renal failure. 2000 , 5, 161-165	
416	Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. 2000 , 95, 2983-2989	240
415	Erythropoietin Therapy in Peritoneal Dialysis Patients. 2000 , 20, 178-182	5
414	The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. 2000 , 15, 2014-9	89
413	Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. 2000 , 11, 1891-900	84
412	Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. 2000 , 139, 1000-8	22
411	Venous thromboembolism in end-stage renal disease. 2000 , 36, 405-11	26
410	Hematocrit levels and associated Medicare expenditures. 2000 , 36, 282-93	48
409	The blood in systemic disorders. 2000 , 355, 1707-12	102
408	Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. 2001 , 24, 87-117	58
407	Development and characterization of novel erythropoiesis stimulating protein (NESP). 2001 , 84 Suppl 1, 3-10	375
406	IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. 2001 , 37, S182-238	505
405	Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. 2001 , 37, 750-7	77

404	Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes. 2001 , 38, 1-7	4
403	Beyond erythropoiesis: novel applications for recombinant human erythropoietin. 2001 , 38, 33-9	45
402	The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era. 2001 , 24, 183-185	4
401	Influence of Recombinant Human Erythropoietin Therapy on Plasma Endothelin-1 Levels during Hemodialysis. 2001 , 24, 367-373	13
400	Delivery of erythropoietin with a needleless injection system during hemodialysis maintains plasma levels. 2001 , 47, 608-10	3
399	Risk factors for cardiovascular disease in children on maintenance dialysis. 2001 , 8, 180-90	16
398	Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. 2001 , 60, 741-7	138
397	Anemia and fatigue in cancer patients. 2001 , 92, 1719-24	31
396	Determinants of mean arterial pressure and pulse pressure in chronic haemodialysis patients. 2001 , 15, 775-9	18
395	Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. 2001 , 16, 111-4	66
394	Implications for the role of endogenous nitric oxide inhibitors in hemodialysis hypotension. 2001 , 35, 341-65	2
393	Trends in anemia management among US hemodialysis patients. 2002 , 13, 1288-95	57
392	Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. 2002 , 13, 1412-4	45
391	Pharmacologic and cytokine treatment of commonly encountered anemias. 2002 , 7, 49-59	
390	Potential cost savings of erythropoietin administration in end-stage renal disease. 2002 , 112, 169-75	43
389	Erythropoietin Use in Pediatric Oncology. 2002 , 4, 20-25	
388	Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. 2002 , 40, 110-8	174
387	Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. 2002 , 40, 119-25	60

386	Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients. 2002 , 27, 111-9	3
385	Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. 2002 , 62, 2167-75	134
384	Influence of target hemoglobin in dialysis patients on morbidity and mortality. 2002 , 44-8	45
383	Evaluation of coagulation and fibrinolysis in haemodialysis patients at different haematocrit levels: Comparison between patients with and without diabetes. 2002 , 7, 37-42	
382	Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia*. 2002 , 7, 315-323	2
381	Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia*. 2002 , 7, S173-S180	4
380	Morbidity and mortality in children with anemia at initiation of dialysis. 2003 , 18, 1055-62	85
379	Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. 2003 , 41, 1233-9	63
378	Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. 2003 , 31, 290-9	350
377	The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. 2003 , 64, 715-9	36
376	Hemoglobin variability in epoetin-treated hemodialysis patients. 2003 , 64, 1514-21	92
375	Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. 2003 , 63, 1086-93	30
374	Thrombosis in end-stage renal disease. 2003 , 16, 245-56	106
373	Transfusion medicine: discipline with a future. 2003 , 43, 823-8	10
372	The use of erythropoietin. 2003 , 33, 1245-60	17
371	The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. 2003 , 25, 1786-805	92
370	Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. 2003 , 14, 2654-61	32
369	Recombinant erythropoietin in clinical practice. 2003 , 79, 367-76	63

368	Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia. 2003 , 3, 501-8	10
367	A case of erythropoietin induced hypertension in a bilaterally nephrectomized patient. 2003 , 49, 131-5	4
366	Erythropoietin: physiology and pharmacology update. 2003 , 228, 1-14	550
365	Autologous stem-cell transplantation can be performed safely without the use of blood-product support. 2004 , 22, 4087-94	42
364	Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. 2004 , 24, 453-60	58
363	Abnormally high serum ferritin levels among professional road cyclists. 2004 , 38, 704-8	22
362	Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. 2004 , 20, 437-43	31
361	Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. 2004 , 65, 266-73	37
360	Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. 2004 , 65, 757-67	72
359	Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. 2004 , 66, 832-40	39
358	Improved survival with higher hematocrits: where is the evidence?. 2004 , 17, 181-3	10
357	The dose of dialysis in hemodialysis patients: impact on nutrition. 2004 , 17, 479-88	17
356	Mechanisms and treatment of anemia in chronic heart failure. 2004 , 10, 243-7	17
355	Iron therapy in the pediatric hemodialysis population. 2004 , 19, 655-61	46
354	Treatment of anemia in patients with chronic heart failure. 2004 , 10, S13-6	12
353	Clinical and economic comparison of epoetin alfa and darbepoetin alfa. 2004 , 20, 381-95	40
352	Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. 2004 , 64, 499-509	66
351	Neurological complications in renal failure: a review. 2004 , 107, 1-16	293

350	Control of blood loss in the treatment of a Jehovah's Witness with massive thermal injuries using a fibroblast derived temporary skin substitute. 2004 , 30, 483-7	2
349	Prevalence and control adequacy of hypertension in a large renal unit. 2004 , 36, 1812-4	
348	The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis. 2004 , 36, 1805-11	2
347	Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. 2004 , 57, 1086-95	45
346	2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. 2004 , 8, 443-59	59
345	Antepartum Hemorrhage. 2004 , 87-109	1
344	Erythropoietin in Sports. 2005 , 4, 224-226	5
343	The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. 2005 , 9, 255-63	10
342	Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?. 2005 , 18, 22-9	11
341	Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. 2005 , 68, 1337-43	199
340	Darbepoetin alfa (Aranesp) in children with chronic renal failure. 2005 , 68, 1759-65	30
339	The anaemia of cancer: death by a thousand cuts. 2005 , 5, 543-55	128
338	K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. 2005 , 45, 16-153	184
337	Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. 2005 , 46, 481-8	55
336	Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. 2005 , 20, 1622-9	28
335	Erythropoietic Agents in Peritoneal Dialysis. 2005 , 25, 547-550	1
334	Argumentaire. 2005 , 1, S9-S48	
333	Anatomy and physiology of hematopoiesis. 69-105	4

332	Correlation between Fractional Reabsorption of Sodium and Erythropoietin dose in Peritoneal Dialysis Patients. 2006 , 26, 581-586	1
331	Erythropoiesis-stimulating agents in kidney and cardiac disease. 2006 , 67, 533-7	2
330	Biosimilars: how similar or dissimilar are they?. 2006 , 11, 341-6	63
329	Nonhematologic complications of erythropoietin therapy. 2006 , 19, 279-84	24
328	[Thrombocytopathy and blood complications in uremia]. 2006 , 118, 134-50	11
327	References. 2006 , 47, S132-S145	
326	Controversies in renal anemia management. 2006 , 35, 120-135	
325	Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. 2006 , 1, 1205-10	137
324	Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. 2006 , 113, 2454-61	286
323	The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?. 2007 , 72, 806-13	28
322	Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. 2007 , 148, 5081-7	42
321	Through the looking glass: anemia guidelines, vested interests, and distortions. 2007 , 2, 415-7	5
320	Dose requirements among hemodialysis patients treated with darbepoetin-alpha or epoetin-beta. 2007 , 107, c50-5	
319	Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. 2007 , 2, 1274-82	97
318	Secondary hypertension due to drugs and toxins. 2007 , 100, 692-9; quiz 700, 708	11
317	Pathogenesis of Seizures During Recombinant Human Erythropoietin Therapy. 2007 , 4, 163-167	3
316	Factors Affecting the Response to Erythropoietin in Chronic Renal Failure. 2007 , 4, 5-8	3
315	How Well Is Hypertension Controlled in Hemodialysis Patients?. 2007 , 5, 99-102	1

314	Nutritional Implications of Erythropoietin Therapy in Dialysis Patients. 2007 , 5, 254-256	
313	Erythropoietin Is Not a Cause of Access Thrombosis. 2007 , 6, 180-184	7
312	Erythropoietin Is a Cause of Access Thrombosis. 2007 , 6, 184-188	10
311	Optimization of Iron Therapy in Hemodialysis Patients Treated with rHuEPO. 2007 , 7, 288-292	4
310	SEIZURES: III. 2007 , 7, 45-47	
309	Association of anemia correction with health related quality of life in patients not on dialysis. 2007 , 23, 2997-3008	49
308	Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. 2007 , 82, 1371-80	27
307	Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. 2007 , 1, 14	22
306	Effects of recombinant human erythropoietin on echocardiographic findings in elderly dialysis patients. 2007 , 3, 149-154	2
305	Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. 2007 , 12, 120-5	3
304	Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. 2007 , 12, 431-6	9
303	Organizing a Dialysis Research Program: The UCLA Experience. 2007 , 11, 82-87	
302	EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. 2007 , 49, 135-42	27
301	New alternatives for erythropoietin therapy in chronic renal failure. 2007 , 2, 361-378	1
300	Erythropoietin pharmacology. 2007 , 9, 715-22	16
299	Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. 2008 , 25, 1215-28	35
298	Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study. 2008 , 12, 469-74	
297	Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. 2008 , 29, 1383-90	22

296	Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. 2008 , 154, 529-41	75
295	Epoetin-associated pure red cell aplasia: past, present, and future considerations. 2008 , 48, 1754-62	134
294	Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. 2008 , 48, 2008-25	22
293	Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. 2008 , 52, 727-36	110
292	Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. 2008 , 52, 897-906	122
291	Normalization of hemoglobin in patients with CKD may cause harm: but what is the mechanism?. 2008 , 52, 642-4	5
290	CERA: third-generation erythropoiesis-stimulating agent. 2008 , 9, 839-49	31
289	Anemia in cystic fibrosis: incidence, mechanisms, and association with pulmonary function and vitamin deficiency. 2008 , 23, 557-63	33
288	Anemia in Chronic Kidney Disease Patients. 2008 , 6, 5-13	
287	Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. 2008 , 24, 625-37	66
286	Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. 2009 , 24, 990-6	28
285	The trend toward geriatric nephrology. 2008 , 35, 515-30, vii	6
284	Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. 2008 , 65, 1711-9	12
283	The effect of altitude on dosing and response to erythropoietin in ESRD. 2008 , 19, 1389-95	49
282	Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. 2008 , 6, 93-102	38
281	Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. 2008 , 74, 791-8	368
280	The effect of epoetin dose on hematocrit. 2008 , 73, 347-53	24
279	The effect of epoetin dose on hematocrit. 2008 , 74, 827; author reply 827-8	

278	Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. 2009 , 24, 919-25	33
277	Hematopoietic cytokines. 2008 , 111, 485-91	405
276	Use of Erythropoietic-Stimulating Agents in Hemodialysis Patients. 2008 , 771-786	
275	Perioperative Evaluation of Patients with Hematologic Disorders. 2008 , 117-156	
274	Erythropoietin, Anemia and Kidney Disease. 2009 , 49-60	2
273	Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. 2009 , 83, 122-30	22
272	Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. 2009 , 75, 358-65	8
271	Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. 2009 , 20, 1436-41	19
270	Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). 2009 , 4, 470-80	126
269	Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters. 1994 , 53, 265-70	16
268	Cisplatin inhibits erythroid committed progenitor (BFU-E) mobilization in peripheral blood. 1998 , 61, 65-70	1
267	Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study. 2009 , 31, 1046-53	6
266	Erythropoietin and erythropoiesis. 2009 , 37, 1007-15	80
265	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). 2009 , 54, 59-69	48
264	Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. 2009 , 54, 498-510	27
263	Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. 2009 , 18, 932-40	23
262	Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. 2009 , 9, 10	29
261	Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alfa or darbepoetin alpha. 2009 , 14, 689-95	9

260	Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. 2009 , 22, 64-9	8
259	The normal hematocrit cardiac trial revisited. 2009 , 22, 495-502	12
258	A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. 2009 , 361, 2019-32	1695
257	Manejo de la eritropoyetina humana recombinante en pacientes con enfermedad renal crónica en estadio IV. 2009 , 30, 37-41	
256	[Hemoglobin rate and cardiovascular risk]. 2009 , 5, 10-4	0
255	Is normalising haemoglobin in patients with CKD harmful and if so, why?. 2009 , 35 Suppl 2, 25-8	2
254	What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?. 2009 , 16, 131-42	25
253	Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. 2009 , 4, e5894	73
252	Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. 2009 , 339, b4018	64
251	Hypertension artérielle d'origine médicamenteuse et toxique. 2010 , 5, 1-8	
250	Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience. 2010 , 17, 469-75	4
249	Hematopoietic Agents. 2010 , 567-608	
248	Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. 2010 , 14, 445-52	14
247	Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. 2010 , 27, 941-52	31
246	Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?. 2010 , 24, 151-60	45
245	Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. 2010 , 55, 113-20	15
244	TREAT: Implications for guideline updates and clinical care. 2010 , 55, 984-7	2
243	Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION. 2010 , 50, 2542-6	12

242	Erythropoietin bundling: innovative remuneration or the dawn of EPO-profiling?. 2010 , 23, 88-90	
241	Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. 2010 , 23, 486-91	2
240	2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. 2010 , 14, 240-75	170
239	Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis. 2010 , 32, 336-43	5
238	Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of <i>Chlamydomonas reinhardtii</i> . 2010 , 8, 719-33	219
237	Anemia in Chronic Kidney Disease. 2010 , 87-97	1
236	Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients. 2010 , 5, 1621-7	2
235	Erythropoietic response and outcomes in kidney disease and type 2 diabetes. 2010 , 363, 1146-55	344
234	Antiviral therapy in HCV-infected decompensated cirrhotics. 2010 , 16, 310-4	6
233	Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate. 2010 , 5, 1340-6	14
232	Recombinant Human Erythropoietin Therapy in Predialysis Patients of Chronic Kidney disease. 2010 , 2, 43-46	
231	Darbepoetin alfa and chronic kidney disease. 2010 , 362, 653; author reply 655	7
230	Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. 2010 , 20, 1219-45	70
229	Anemia management in chronic kidney disease. 2010 , S3-9	17
228	Anaemia management in cardio renal disease. 2010 , 36 Suppl 1, 86-96	8
227	Erythropoietin and iron therapy in patients with renal failure. 2010 , 11, 20-29	
226	Erythropoietic stimulating agents. 2010 , 15, 119-38	13
225	Principles of Hemodialysis. 2010 , 277-302	1

224	Red blood cell survival in long-term dialysis patients. 2011 , 58, 591-8	102
223	Today's challenges in pharmacovigilance: what can we learn from epoetins?. 2011 , 34, 273-87	16
222	Transfusion medicine for pathologists. 2011 , 619-639	
221	[TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4]. 2011 , 7, 2-9	6
220	Dialysis time: does it matter? A reappraisal of existing literature. 2011 , 20, 189-94	8
219	Dialysis patients treated with Epoetin ß show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial. 2011 , 15, 87-94	8
218	Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study. 2011 , 43, 1593-600	5
217	Relationship of erythropoiesis-stimulating agent dose and responsiveness and adverse outcomes in CKD. 2011 , 57, 661-3	3
216	Incorporating short-term outcome information to predict long-term survival with discrete markers. 2011 , 53, 294-307	12
215	C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. 2011 , 26, 3980-6	40
214	Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. 2011 , 6, 2579-86	24
213	Renal Association Clinical Practice Guideline on anaemia of chronic kidney disease. 2011 , 118 Suppl 1, c101-24	4
212	Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. 2011 , 22, 358-65	45
211	Dosing of erythropoiesis-stimulating agents can be reduced by a new administration regimen. 2011 , 1, 45-54	
210	What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. 2011 , 124, 2805-8	5
209	Hemodialysis treatment time: a fresh perspective. 2011 , 6, 2522-30	25
208	Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. 2012 , 15, 293-304	9
207	Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices. 2012 , 78, 157-61	2

206	Changing patterns of anemia management in US hemodialysis patients. 2012 , 125, 906-14.e9	48
205	Cost-effectiveness of Treating Chronic Anemia with Epoetin Alfa among Hemodialysis Patients in the United States. 2012 , 3, e79-e89	2
204	The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?. 2012 , 59, 604-6	2
203	The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases. 2012 , 26, 363-9	22
202	Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations. 2012 , 27, 339-50	21
201	Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. 2013 , 37, 549-58	88
200	Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. 2013 , 52, 1063-83	14
199	Update on erythropoiesis-stimulating agents. 2013 , 27, 121-9	9
198	A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. 2013 , 74, 5-8	6
197	Anaemia management and mortality risk in chronic kidney disease. 2013 , 9, 291-301	90
196	Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration. 2013 , 62, 1046-57	32
195	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. 2013 , 61, 238-46	15
194	Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. 2013 , 368, 320-32	85
193	Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. 2013 , 8, 965-76	13
192	Plasma vascular endothelial growth factor and angiogenin are positively related to erythropoietin dose in hemodialysis patients. 2013 , 58, 143-9	2
191	A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. 2013 , 69, 929-36	24
190	Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control. 2013 , 1, 51-69	19
189	Drug-induced cardiovascular adverse events in the intensive care unit. 2013 , 36, 323-34	5

188	Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. 2013 , 8, 538-45	6
187	What is the value of L-carnitine level determination for carnitine supplementation in hemodialysis patients?. 2013 , 17, 335-8	1
186	Novel drugs and intervention strategies for the treatment of chronic kidney disease. 2013 , 76, 536-50	32
185	Subcutaneous versus intravenous erythropoietin for long-term dialysis patients. 2013 ,	
184	Cost-effectiveness of continuous erythropoietin receptor activator in anemia. 2014 , 6, 319-30	11
183	The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. 2014 , 10, 641-50	20
182	Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. 2014 , 46, 1983-95	2
181	Structural identification of modified amino acids on the interface between EPO and its receptor from EPO BRP, human recombinant erythropoietin by LC/MS analysis. 2014 , 37, 819-26	9
180	Evaluation and management of anemia in the elderly. 2014 , 89, 88-96	150
179	Erythropoietin and resistant hypertension in CKD. 2014 , 34, 540-9	15
178	Side effects of cytokines approved for therapy. 2014 , 37, 921-43	84
177	Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). 2014 , 174, 699-707	15
176	Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin. 2014 , 46, 161-7	14
175	Assessment and management of hypertension in patients on dialysis. 2014 , 25, 1630-46	106
174	Moving away from hemoglobin-based anemia performance measures in dialysis patients. 2014 , 64, 486-8	1
173	Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. 2014 , 19, 735-9	18
172	Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study. 2014 , 15, 119	7
171	Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients. 2014 , 89, 87-94	234

170	Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?. 2014 , 113, 3-10	29
169	Development of a standardized transfusion ratio as a metric for evaluating dialysis facility anemia management practices. 2014 , 64, 608-15	8
168	WITHDRAWN: A review on pharmacological use of recombinant human erythropoietin in renal and non-renal anemia and other potential applications in clinical practice. 2014 ,	
167	Effect of erythropoietin on primed leucocyte expression profile. 2014 , 4, 140026	6
166	Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. 2015 , 5, 79-86	3
165	Subcutaneous versus intravenous erythropoietin for long-term dialysis patients. 2015 ,	
164	Trends in Anemia Management in Hemodialysis Patients with Cancer. 2015 , 42, 206-15	8
163	Successful creation of an anemia management algorithm for hemodialysis patients. 2015 , 8, 65-75	5
162	High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis. 2015 , 3, 258	7
161	Left ventricular assist device thrombosis: another piece of the puzzle?. 2015 , 3, 154-8	7
160	Acetylsalicylic acid mitigates erythropoietin-associated blood pressure increase in nonuremic rats. 2015 , 37, 235-40	
159	CRIT-LINE: a noninvasive tool to monitor hemoglobin levels in pediatric hemodialysis patients. 2015 , 30, 991-8	2
158	Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. 2015 , 10, 1822-30	25
157	Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. 2015 , 35, 481-9	3
156	Hematologic Complications of Chronic Kidney Disease. 2015 , 266-276	1
155	Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. 2016 , 31, 55-60	2
154	Prevalence and management of anemia in pre-dialysis Malaysian patients: A hospital-based study. 2016 , 62, 742-747	5
153	Anemia in Chronic Renal Disease. 2016 , 1507-1532	

152	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. 2016 , 151, 147-156	4
151	Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. 2016 , 11, 982-91	190
150	Investigational therapies for renal disease-induced anemia. 2016 , 25, 901-16	24
149	Carbamylated erythropoietin enhances mice ventilatory responses to changes in O ₂ but not CO ₂ levels. 2016 , 232, 1-12	2
148	Hematopoietic Growth Factors in Transfusion Medicine. 2016 , 474-491	
147	Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis. 2016 , 18, 125	4
146	Drug-Induced Hypertension in Chronic Kidney Disease. 2016 , 261-298	
145	Hypertension in the Dialysis Patient. 2016 , 133-166	
144	Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?. 2016 , 18, 23	14
143	The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. 2016 , 36, 421-31	7
142	A review on pharmacological use of recombinant human erythropoietin in renal and nonrenal anemia and other potential applications in clinical practice. 2016 , 13, 80-85	2
141	Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn). 2017 , 30, 142-148	5
140	Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. 2017 , 7, 44013	4
139	Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. 2017 , 32, 1373-1386	120
138	A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats. 2017 , 7, 318-323	17
137	Blood Loss in Orthopedic Surgery: A Historical Review. 2017 , 32, 2-11	0
136	Developing a classification system for haemoglobin management in patients with end-stage renal disease on haemodialysis: a secondary data analysis. 2017 , 7, e017423	
135	What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease. 2017 , 30, 29-31	

134	Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. 2017 , 12, e0172735	8
133	Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. 2017 , 18, 345	117
132	Use of Erythropoiesis-Stimulating Agents in Hemodialysis Patients. 2017 , 563-570.e1	
131	Improving Erythropoiesis Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: The Role of Heparin and Hemodiafiltration Online. 2018 , 45, 139-146	12
130	Anemia of Chronic Kidney Disease. 2018 , 113-127	1
129	Computational Intelligence Methods in Personalized Pharmacotherapy. 2018 , 325-333	
128	Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclists. 2018 , 6, e13924	3
127	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. 2018 , 72, e53-e90	333
126	Hypertension and Chronic Kidney Disease. 2018 , 311-320	
125	Roxadustat and Anemia of Chronic Kidney Disease. 2019 , 381, 1070-1072	21
124	Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. 2019 , 381, 1001-1010	235
123	Kidney Disease and Anemia in Elderly Patients. 2019 , 35, 327-337	3
122	The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. 2019 , 26, 229-236	2
121	Resistant Hypertension Updated Guidelines. 2019 , 21, 117	10
120	A new approach to treating renal anaemia. 2019 , 15, 731-732	6
119	Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. 2019 , 30, 1037-1048	43
118	Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis. 2019 , 66, 716-731	36
117	Anemia in Chronic Kidney Disease. 2019 , 136-144.e6	1

116	Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. 2019 , 98, e13981	3
115	Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach. 2020 , 36, 26-36	5
114	Peripheral nerve injury and myelination: Potential therapeutic strategies. 2020 , 98, 780-795	33
113	Effect of fetal bovine serum on erythropoietin receptor expression and viability of breast cancer cells. 2020 , 27, 653-658	2
112	Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. 2020 , 33, 267-275	
111	Clinical and genetic markers of erythropoietin deficiency anemia in chronic kidney disease (predialysis) patients. 2020 , 14, 1099-1108	2
110	Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. 2020 , 9,	7
109	Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Health Care Data □ Implications for Clinical Management and Clinical Trial Design. 2020 , 447-468	
108	Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients. 2020 , 7, 2054358120927532	1
107	The journey from erythropoietin to 2019 Nobel Prize: Focus on hypoxia-inducible factors in the kidney. 2021 , 120, 60-67	5
106	Hematopoietic Agents. 1-42	
105	Anemia management: a historical perspective. 2021 , 11, 3-7	1
104	Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. 2021 , 9, 3680-3688	
103	Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan. 2021 , 10, e019529	1
102	In-Center Hemodialysis. 2021 , 20, 3-18	
101	S1P Stimulates Erythropoietin Production in Mouse Renal Interstitial Fibroblasts by S1P and S1P Receptor Activation and HIF-2β Stabilization. 2021 , 22,	5
100	Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients. 2021 ,	0
99	Anemia and fatigue in cancer patients. 2001 , 92, 1719-1724	31

98	Peritoneal Dialysis in Children. 2009 , 803-859	4
97	Blood Pressure Control in Chronic Hemodialysis Patients. 1996 , 966-989	5
96	The Role of Other Hemopoietic Growth Factors and the Marrow Microenvironment in Megakaryocytopoiesis. 1997 , 165-178	2
95	Management of Renal Anemia in Children with Chronic Kidney Disease. 2012 , 531-568	1
94	The Management of Coronary Artery Disease in Patients with End-Stage Renal Disease. 1992 , 231-246	5
93	Hematologic Problems. 1997 , 627-636	2
92	Erythropoietin use and abuse. 2001 , 207-224	30
91	Use of erythropoietic stimulating agents in the setting of renal disease. 2009 , 225-248	1
90	Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin. 2009 , 77-85	3
89	Peritoneal dialysis in children. 1994 , 591-637	11
88	Psychosocial aspects of heart transplantation: a comparative analysis. 1992 , 469-482	3
87	Peritoneal dialysis in children. 2000 , 667-708	6
86	Quality of life after peritoneal dialysis. 2000 , 709-735	4
85	Anemia in Patients with End-Stage Renal Disease. 2008 , 761-770	2
84	Hemodialysis. 2012 , 2294-2346	4
83	Uremic bleeding: pathogenesis and therapy. 1998 , 316, 94-104	142
82	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+Cells. 1998 , 92, 472-480	28
81	Hematocrit level and associated mortality in hemodialysis patients. 1999 , 10, 610-9	374

80	An indistinct balance: the safety and efficacy of parenteral iron therapy. 1999 , 10, 2029-43	75
79	Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. 2000 , 11, 530-538	176
78	The use of erythropoietin in the management of Jehovah's Witnesses who have revision total hip arthroplasty. 1996 , 78, 1548-52	23
77	Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia. 2006 , 2, 175-86	4
76	Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. 2014 , 11, 100-5	4
75	2008 JSDT "Guideline for Renal Anemia in Chronic Kidney Disease". 2008 , 41, 661-716	29
74	Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. 2008 , 14, 151-7	8
73	Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. 2014 , 69, 547-53	2
72	Biphasic changes in nitric oxide generation in hemodialyzed patients with end-stage renal disease treated with recombinant human erythropoietin. 2000 , 319, 149-57	
71	Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa. 2002 , 9-27	
70	Novel Applications for Recombinant Human Erythropoietin. 2002 , 197-206	
69	Has the best route of administration for epoetin been established?. 2002 , 15-28	
68	Anemia and erythropoietin therapy in kidney transplant recipients: where are the data?. 2002 , 123-128	
67	Hematopoietic Agents. 2003 , 251-281	
66	Anhien. 2003 , 1013-1027	2
65	Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment. 2003 , 96, 491-3	
64	Blood pressure control in chronic hemodialysis patients. 2004 , 741-764	
63	Management of anemia in patients with chronic kidney disease. 2004 , 927-963	

- 62 Management of renal anemia. **2004**, 295-331 1
- 61 Hematologic manifestations of systemic illness. **2005**, 71-93 1
- 60 New molecules and formulations. **2009**, 115-140
- 59 Renal Failure. **2010**, 1257-1281
- 58 Two cases of thrombocytopenia after discontinuation of darbepoetin-The effect of erythropoiesis stimulating agent(ESA) on thrombocytes-. **2010**, 43, 523-530
- 57 Erythropoietin and Iron Therapy in Patients with Renal Failure. 357-367
- 56 Dietary Approaches to Kidney Diseases. **2011**, 2170-2204 2
- 55 Hematopoietic Growth Factors in Transfusion Medicine. 474-491
- 54 Adequate administration of darbepoetin alfa improves renal anemia in Japanese peritoneal dialysis patients for whom the maximum dose of recombinant human erythropoietin did not fully achieve improved anemia. **2012**, 45, 247-253
- 53 Investigation of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in hemodialysis patients. **2013**, 46, 641-649
- 52 Anemia and nutrition in end stage renal disease patient. **2013**, 56, 592 2
- 51 Use of Recombinant Human Erythropoietin in Anemic Dialysis Patients. **1990**, 233-238
- 50 Erythropoietin: its role in the regulation of erythropoiesis and as a therapeutic in humans. **1991**, 19, 351-63
- 49 Erythropoietin in the Anemia of End-Stage Renal Disease. **1992**, 223-265
- 48 Anemias. **1992**, 917-930
- 47 Transfusion Medicine: The Impact of Biotechnology, Growth Factors, and Bioengineering. **1992**, 153-158
- 46 Erythropoietin Treatment in Allogeneic Bone Marrow Transplantation: A Prospective and Randomized Trial. **1992**, 635-640
- 45 Use of Recombinant Human Erythropoietin in the Anemia of Progressive Renal Failure. **1992**, 231-241

44 Rehabilitation of elderly patients on hemodialysis. **1993**, 277-291

43 Biotechnology Products: An Overview. **1993**, 381-401

42 The Humoral Regulation of Normal and Pathologic Erythropoiesis. **1993**, 47-70

41 Therapie der Anämien. **1995**, 517-532

40 Anemia and Its Treatment in Children on CAPD/CCPD. **1998**, 183-197

2

39 Chronic Transfusion Support. **1998**, 177-188

38 The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+ Cells. **1998**, 92, 472-480

2

37 Central Nervous System Toxicities of Cytokine Therapy. **1998**,

36 Therapie der Anämien. **1999**, 925-940

1

35 The Use of Recombinant Erythropoietin in the Treatment and Prevention of Cancer and Chemotherapy-related Anemia. **1999**, 198-216

34 Microenvironment Applications. 4652-4670

33 Genomics, Other Omics Technologies, Personalized Medicine, and Additional Biotechnology-Related Techniques. **2016**, 149-190

32 Anämien. **2005**, 1063-1077

31 Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin. **2003**, 15-23

30 Use of recombinant erythropoietins in the setting of renal disease. **2003**, 153-161

0

29 Hematological Problems of Renal Failure. **1996**, 1059-1076

28 Anemia Management. **2008**, 337-356

27 Clinical use of erythropoietin. **1992**, 156, 73-4

2

26	Erythropoietin therapy in patients with chronic renal failure. 1992 , 157, 154-7	7
25	Platelet parameters in women with iron deficiency anemia. 2006 , 98, 398-402	57
24	Erythropoietin: current status. 1990 , 63, 381-6	5
23	A review of the first year of Medicare coverage of erythropoietin. 1994 , 15, 83-102	3
22	BLOOD SUPPLY CHAIN: AN ANALYSIS OF DIVERSE CLINICAL CONDITIONS IN LIGHT OF THE IMPORTANCE OF LABORATORY TECHNIQUES AND TRANSFUSION ISSUES. A RETROSPECTIVE ANALYSIS OF HOSPITAL-BASED INCIDENTS. 2021 , 49-50	
21	A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure. 2021 , 22, 391	o
20	Efficacy and safety of recombinant human erythropoietin (Hema-Plus) for management of anemia in Thai patients on peritoneal dialysis.. 2021 , 10, 109-121	o
19	Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial.. 2022 , 23, 100	o
18	Normal Erythropoietin Response in Chronic Hepatitis C Patients with Ribavirin-Induced Anaemia. 2003 , 8, 57-63	8
17	Sphk1 and Sphk2 Differentially Regulate Erythropoietin Synthesis in Mouse Renal Interstitial Fibroblast-like Cells. 2022 , 23, 5882	1
16	Cyclic thrombocytopenia related to erythropoietin-dependent anti-platelet anti-GPIV/IIIb antibody in hemodialysis.	o
15	Case Report: Let Us Not Forget the Treatment That Some Patients Have Received The Brief 50-Year History of a Kidney Transplant Survivor. 9,	o
14	The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. 2022 , 12, 1175	1
13	Anemia and Its Treatment in Patients With End-Stage Kidney Disease. 2023 , 341-350	
12	Association between hyporesponsiveness to erythropoiesis-stimulating agents and risk of brain hemorrhage in patients undergoing hemodialysis: the Q-Cohort Study.	o
11	Status and Treatment of Renal Anemia in Pa-tients with Maintenance Peritoneal Dialysis. 2022 , 12, 9898-9904	o
10	Physician Compliance with Computerized Clinical Decision Support System is a Complete Intermediate Factor in the Anemia Management of Patients with End-Stage Kidney Disease on Hemodialysis: A Retrospective Electronic Health Record Observational Study (Preprint).	o
9	The role of roxadustat in chronic kidney disease patients complicated with anemia.	o

- 8 Biosimilarity of GBPD002 compared with Eprex® through clinical evaluation in human. o
- 7 Development and qualification of a high-yield recombinant human Erythropoietin biosimilar. o
- 6 Safety of High Dose Erythropoietin Used with Therapeutic Hypothermia as Treatment for Newborn Hypoxic-Ischemic Encephalopathy: Secondary Analysis of the HEAL Randomized Controlled Trial. **2023**, 113400 o
- 5 Multi-head self-attention mechanism enabled individualized hemoglobin prediction and treatment recommendation systems in anemia management for hemodialysis patients. **2023**, 9, e12613 o
- 4 Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism. **2023**, 24, 3037 o
- 3 Hyporesponsiveness to Erythropoietin-Stimulating Agents: Possible Solutions. o
- 2 Physician Compliance with Computerized Clinical Decision Support System is a Complete Intermediate Factor in the Anemia Management of Patients with End-Stage Kidney Disease on Hemodialysis: A Retrospective Electronic Health Record Observational Study (Preprint). o
- 1 Anemia in Chronic Renal Disease. **2023**, 1603-1630 o